1109277-52-2Relevant academic research and scientific papers
Discovery of PF-04620110, a potent, selective, and orally bioavailable inhibitor of DGAT-1
Dow, Robert L.,Li, Jian-Cheng,Pence, Michael P.,Gibbs, E. Michael,Laperle, Jennifer L.,Litchfield, John,Piotrowski, David W.,Munchhof, Michael J.,Manion, Tara B.,Zavadoski, William J.,Walker, Gregory S.,McPherson, R. Kirk,Tapley, Susan,Sugarman, Eliot,Guzman-Perez, Angel,Dasilva-Jardine, Paul
, p. 407 - 412 (2011)
Acyl-CoA:diacylglycerol acyltransferase-1 (DGAT-1) catalyzes the final committed step in the biosynthesis of triglycerides. DGAT-1 knockout mice have been shown to be resistant to diet-induced obesity and have increased insulin sensitivity. Thus, inhibiti
4-AMINO-5-OXO-7, 8-DIHYDROPYRIMIDO [5,4-F] [1,4] OXAZEPIN-6 (5H) -YL) PHENYL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
-
Page/Page column 32-33, (2010/08/09)
The invention provides compounds of Formula (I), wherein R1, R2a, R2b, R3, m and A are as defined herein, as well as compositions thereof and methods for treating a disease, condition or disorder that is modulated by the inhibition of the diacylglycerol O-acyltransferase 1 (DGAT-1) enzyme by administering the compounds of the present invention and/or compositions thereof.
SUBSTITUTED BICYCLOLACTAM COMPOUNDS
-
Page/Page column 13, (2009/03/07)
The invention provides compounds of formula (1), and the pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5a, R5b, R5c, R5d, Q, A, Z, and R7 /s
